Development and Validation of an Alternative HPLC-DAD Method for Cisplatin Analysis in Solution

Cisplatin is a widely used chemotherapeutic agent, and its precise & accurate quantification in solutions is crucial because these methods could be further used for its determination in pharmaceutical formulations and biological matrices. Here, a novel, rapid, and reliable reversed-phase isocratic HPLC method was developed and validated for the determination of cisplatin in solution. The resolution was achieved using a C18 column as the stationary phase and a mixture of methanol:sodium dodecyl sulphate (MeOH:SDS, 0.5 mM, 30:70) with a flow rate of 0.5 mL/min as the mobile phase. The detection was carried out at 204 nm, and the analysis was completed within seven minutes. The validation of the proposed method, which is easy, fast, and does not require the use of any acid or base, was performed in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals (ICH Q2(R2)). Depending on the findings, the developed method showed high linearity over the concentration range of 20-150 μg/mL. The limit of detection (LOD) and limit of quantitation (LOQ) were determined to be 7.37 and 22.33 μg/mL, respectively. Compared with previously reported methods, the proposed method demonstrated superior performance, with a wider linear range and acceptable LOD and LOQ. The system suitability parameters, including retention time, number of plates, height equivalent of a theoretical plate (HETP), area, tailing, and resolution, were evaluated. According to the obtained results, the developed method showed excellent chromatographic performance, characterized by high resolution, acceptable tailing, and a short analysis time.